clinical practice needs to be quantified. Certainly, the area of failure for vascular access devices, central and peripheral devices, needs to be explored more. We’ ve focused, quite rightly, on reducing infection, and to some degree we’ ve had big success and changes there. We wish to sustain those. The issue of failure due to occlusion or infiltration or dislodgment or localised infection, was unquantified and not realised until recently. Now there is data on that, and we need to tackle that. Then there’ s the issue of removal. Much research has [ indicated there are often ] redundant IVs or‘ just in case’ IVs and [ identified ] the best time to remove an IV once it’ s no longer needed.
clinical practice needs to be quantified. Certainly, the area of failure for vascular access devices, central and peripheral devices, needs to be explored more. We’ ve focused, quite rightly, on reducing infection, and to some degree we’ ve had big success and changes there. We wish to sustain those. The issue of failure due to occlusion or infiltration or dislodgment or localised infection, was unquantified and not realised until recently. Now there is data on that, and we need to tackle that. Then there’ s the issue of removal. Much research has [ indicated there are often ] redundant IVs or‘ just in case’ IVs and [ identified ] the best time to remove an IV once it’ s no longer needed.
The idea that where research evidence does exist there is often a failure to implement it was also discussed at the event. What’ s impeding evidence from being translated into practice? A few things. First, vascular access hasn’ t been‘ owned’ by any one particular group or specialty, and I hope the establishment of a national society [ allows us to ] tackle it collectively. That team approach will certainly have more impact. Second, there’ s just the issue that people, I don’ t think, realised there was a problem before. Vascular access failure wasn’ t realised until recently. Finally, there’ s people’ s understanding and appreciation of research, just the general understanding of the levels of evidence and the powers and methodologies that should have a stronger impact on influencing your practice.
Apart from bolstering research in this area, how can the use of vascular access devices be improved? If we go from the life cycle of the device, if we look at insertion, better patient assessment and looking at better device decisionmaking tools. Looking at the patient, seeing what device is probably best for them for their treatment, and for the duration of that treatment. Patient assessment and device selection, looking at who is the best person to put in that device. We know that can influence the success and the dwell time of that device.
Then there’ s the issue of maintenance. The emphasis is on patient and device assessment but also on the products we use to dress and secure the cannula once it’ s in and also to look after it with regards to flushing.
With regard to dressing and securement, we have done studies in that area, and they didn’ t identify a definitive device to reduce failure. What they did show is that just a simple transparent dressing wasn’ t good enough when compared with more advanced dressings. Using an adjunct such as tissue adhesive or medical grade glue, or using a border polyurethane or suture securement device reduces the risk of dislodgment and the micro-pistoning that contributes to phlebitis and local infection. That’ s one area where practice and products can work together to improve the vascular access experience for the patient and improve outcomes.
Then there’ s the issue of maintaining the functioning of the catheter, and that’ s largely down to how we administer flushing, fluids and medications. We’ re still working on what is the best evidence in that area. Our research has shown that practice is varied and inconsistent, and we can look at streamlining that and conforming to the best guidelines. Part of that is [ documentation ] so we’ ll know that nurses have assessed the patency and functioning of catheters regularly. There are also potential products such as manufacturer prepared pre-filled syringe devices that can reduce the risk of infection and contamination, save time and reduce medication errors with pre-labelling. They can also reduce damage to vessels because they are consistent with 10ml syringes, reducing the risk of damage from using a smaller, higher-pressure syringe.
Then we come to the area of removal. That sometimes ties into [ the question of ]:“ Should it have been in, in the first place?” We come back to patient assessment. That’ s the root of all these areas. Then [ we need ] continuous assessment to determine,“ Is it required? Do we still need it? When is the best time to take that out?”
A number of randomised controlled trials and a significant Cochrane Review have demonstrated that clinically indicated removal is a safer, more cost-effective way to manage peripheral IV devices than routine removal.
What impact could improving the use of vascular access devices have on the work nurses do and on the health system as a whole? Nurses always wish to provide the best care they can for their patients, but they are busy. A number of these [ improvements ] could be time saving. [ That can happen ] if there is evidence-based care, a good rationale and products that, perhaps, have reduced the number of steps a nurse needs to go through to deliver a medication or flush, or manage the device.
For the healthcare service, we’ ve done health economics evaluations that show we can save hundreds of millions of dollars if we can preserve the functioning of catheters. Just within the peripheral devices, there are about 25 million used around Australia, and about 40 per cent of those are failing. It costs about $ 70 to replace each PVRC. We’ re wasting about $ 700 million. If we just reduce that failure rate from 40 per cent to 30 per cent, we’ ll save ourselves millions of dollars, and I’ m sure we can get the failure rate down even lower.
Then, there’ s the ever present risk of infection, less so in peripherals but it’ s still present, and we wish to make it low. The risk of infection in central venous devices equates to hundreds of thousands of dollars in treatment of complications.
What might the future hold in terms of technology in this area? There’ s room for us to use ultrasound to guide the insertion of peripheral intravenous devices. All our patients are getting sicker, [ so many of them ] will identify in the difficult to cannulate category. Again, it comes back to patient assessment. [ Sometimes ] the poor patient goes through three, four, five, six, up to 10 attempts of individuals trying to find a vein with a blind stick. We need to put a stop to that, use a proper patient assessment tool and escalate in a timely manner. If we determine when some patients come in that they’ re difficult to cannulate, then we escalate them straight to an expert inserter who can use ultrasound to help locate their veins and insert, to reduce the pain and discomfort and to optimise their vessel preservation.
That technology is available to us now. We can always dream. For [ long-term ] goals, maybe we can have cannulas that change colour when they’ re due to be changed or are starting to occlude. We can have pressure-limiting devices that mean none of our syringes or bolus deliveries will cause harm to the cannula or the vessel. Perhaps we can have small, portable … devices that the patient can walk around the hospital with and the children can play in the playroom with, rather than cumbersome IV poles and administration sets. There’ s a lot of room for simple and quite advanced technology that can improve the experience and the outcome for the patient and reduce their healthcare costs. ■
nursingreview. com. au | 31